BRPI0517650A - uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca - Google Patents

uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca

Info

Publication number
BRPI0517650A
BRPI0517650A BRPI0517650-6A BRPI0517650A BRPI0517650A BR PI0517650 A BRPI0517650 A BR PI0517650A BR PI0517650 A BRPI0517650 A BR PI0517650A BR PI0517650 A BRPI0517650 A BR PI0517650A
Authority
BR
Brazil
Prior art keywords
remodeling
ranolazine
heart failure
reversal
combination
Prior art date
Application number
BRPI0517650-6A
Other languages
English (en)
Inventor
Brent Blackburn
Hani Naief Sabbah
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of BRPI0517650A publication Critical patent/BRPI0517650A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE RANOLAZINA EM COMBINAçáO COM PELO MENOS UM AGENTE DE REMODELAMENTO PARA REVERSAO DE REMODELAMENTO VENTRICULAR ESQUERDO NO TRATAMENTO DE INSUFICIêNCIA CARDìACA. A presente invenção se refere a um método de reversão do remodelamento do ventrículo esquerdo através de administração combinada de quantidades terapeuticamente eficazes de ranolazina e pelo menos um agente de coremodelamento, o qual pode ser um inibidor de ACE, um ARB ou um beta-bloqueador. O método encontra utilidade no tratamento de insuficiência cardíaca. A presente invenção também se refere à formulações farmacêuticas que são adequadas para tal administração combinada.
BRPI0517650-6A 2004-11-09 2005-11-09 uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca BRPI0517650A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62615404P 2004-11-09 2004-11-09
PCT/US2005/040824 WO2006053161A1 (en) 2004-11-09 2005-11-09 Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Publications (1)

Publication Number Publication Date
BRPI0517650A true BRPI0517650A (pt) 2008-10-14

Family

ID=35892429

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517650-6A BRPI0517650A (pt) 2004-11-09 2005-11-09 uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca

Country Status (15)

Country Link
US (2) US20060111361A1 (pt)
EP (1) EP1809289A1 (pt)
JP (1) JP2008519770A (pt)
KR (1) KR20070084063A (pt)
CN (1) CN101072562A (pt)
AU (1) AU2005304421A1 (pt)
BR (1) BRPI0517650A (pt)
CA (1) CA2586840A1 (pt)
IL (1) IL183056A0 (pt)
MX (1) MX2007005367A (pt)
NO (1) NO20072934L (pt)
RU (1) RU2007121707A (pt)
SG (1) SG156681A1 (pt)
WO (1) WO2006053161A1 (pt)
ZA (1) ZA200703697B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332540A1 (en) * 2002-05-21 2011-06-15 Cv Therapeutics, Inc. Administration of ranolazine for the treatment of diabetes
US9782258B2 (en) * 2006-09-08 2017-10-10 The Regents Of The University Of California Intramyocardial patterning for global cardiac resizing and reshaping
JP2010514696A (ja) * 2006-12-21 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心血管症状の低減
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080214555A1 (en) * 2007-02-13 2008-09-04 Markus Jerling Use of ranolazine for the treatment of cardiovascular diseases
WO2008101008A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
JP2010523264A (ja) * 2007-04-11 2010-07-15 ヘンリー フォード ヘルス システム 心臓の静脈系を用いた心臓の修復、リサイジング、およびリシェイピング
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
WO2008154033A2 (en) * 2007-06-11 2008-12-18 Symphony Medical, Inc. Cardiac patterning for improving diastolic function
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン
CA3130908A1 (en) 2009-06-30 2010-12-30 Mallinckrodt Hospital Products IP Limited Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE223218T1 (de) * 1989-06-23 2002-09-15 Syntex Llc Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
AU8026200A (en) * 1999-10-19 2001-04-30 Board Of Regents, The University Of Texas System Treatment of heart disease with cox-2 inhibitors
JP2004505886A (ja) * 2000-02-18 2004-02-26 スィーヴィー　セラピューティクス　インコーポレイテッド 鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
WO2006053161A1 (en) 2006-05-18
AU2005304421A1 (en) 2006-05-18
US20060111361A1 (en) 2006-05-25
ZA200703697B (en) 2008-09-25
CA2586840A1 (en) 2006-05-18
NO20072934L (no) 2007-08-08
IL183056A0 (en) 2007-10-31
JP2008519770A (ja) 2008-06-12
WO2006053161A8 (en) 2006-09-14
CN101072562A (zh) 2007-11-14
MX2007005367A (es) 2007-06-18
RU2007121707A (ru) 2008-12-20
EP1809289A1 (en) 2007-07-25
KR20070084063A (ko) 2007-08-24
SG156681A1 (en) 2009-11-26
US20090176772A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
BRPI0517650A (pt) uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca
BRPI0706676B8 (pt) uso de uma solução aquosa com potencial de oxirredução
DE60111539D1 (de) Pharmazeutische zusammensetzung enthaltend ein 5-aminolaevulinsäure-ester als photochemotherapeutikum und ein mucoadhäsivum
BRPI0510274B8 (pt) uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico
AR119158A1 (es) Tratamientos de angioedema hereditario
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
ECSP055525A (es) Inhibidores de cinasas de tirosina
NO20053845L (no) Gyraseinhibitorer og anvendelser derav
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CU23821A3 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CO2022000270A2 (es) Inhibidores de enzimas
BRPI0703970A2 (pt) tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.